Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A Phase 1B/2A study of weekly decitabine and venetoclax treatment as maintenance therapy in high-risk myeloid malignancy patients post allogeneic stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

CBClaudio G. BrunsteinCleveland Clinic

Discussion

Loading...

Member takes

Implication

Phase 1B/2A trial shows weekly decitabine and venetoclax improves maintenance therapy for high-risk AML and MDS after transplant, suggesting enhanced outcomes.

Key Points

  • To evaluate the safety and efficacy of weekly decitabine and venetoclax as maintenance therapy in high-risk AML and MDS post allogeneic stem cell transplantation.
  • Open-label, single-arm phase 1B/2A study
  • Involves patients with high-risk AML and MDS post alloSCT
  • Primary assessment of safety and feasibility of decitabine and venetoclax treatment
  • Aim to assess one-year relapse-free survival rates compared to historical controls
  • Exploratory endpoint includes effect on DNMT1 protein levels and immune reconstitution

Cite This Study

Claudio G. Brunstein (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e52ahttps://doi.org/10.1182/blood-2025-2510
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation2025
  2. 2The venetoclax combined with metronomic low-dose decitabine and interferon for preventing post-transplant relapse in high-risk MDS and AML patients2025
  3. 3Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS2025
  4. 4Low‐dose decitabine plus venetoclax as post‐transplant maintenance for high‐risk myeloid malignancies2024 · 6 citations
  5. 5Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML2025 · 4 citations